Disease · MONDO_0021040
Comparisons in its trials99
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 99
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Axitinib + Gemcitabine vs Placebo + Gemcitabine: serious adverse events | 108 of 304 | 102 of 309 | 613 | NCT00471146 | Trial comparisons |
| Placebo and Gemcitabine vs Aflibercept and Gemcitabine: serious adverse events | 122 of 271 | 148 of 270 | 541 | NCT00574275 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Disease Control Rate (DCR) | 147 of 255 | 126 of 257 | 512 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Objective Response Rate (ORR) | 41 of 255 | 32 of 257 | 512 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: deaths from any cause | 209 of 248 | 211 of 246 | 494 | NCT03665441 | Trial comparisons |
| Eryaspase Plus Chemotherapy vs Chemotherapy Alone: serious adverse events | 122 of 248 | 105 of 246 | 494 | NCT03665441 | Trial comparisons |
| Placebo and Gemcitabine vs Aflibercept and Gemcitabine: Number of Participants With Anti-drug Antibodies | 5 of 202 | 5 of 201 | 403 | NCT00574275 | Trial comparisons |
| CO-1.01 vs Gemcitabine: serious adverse events | 82 of 179 | 82 of 181 | 360 | NCT01124786 | Trial comparisons |
| Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX vs Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX: Number of Participants With Best Overall Objective Response as Assessed Using RECIST v1.1 | 43 of 143 | 64 of 141 | 284 | NCT03941093 | Trial comparisons |
| Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX vs Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX: deaths from any cause | 118 of 143 | 112 of 141 | 284 | NCT03941093 | Trial comparisons |
| Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX vs Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX: serious adverse events | 75 of 142 | 62 of 141 | 283 | NCT03941093 | Trial comparisons |
| Nab-Paclitaxel Plus Gemcitabine (Induction Period) vs Nab-Paclitaxel Plus Gemcitabine (Overall): deaths from any cause | 42 of 106 | 67 of 106 | 212 | NCT02301143 | Trial comparisons |
| Nab-Paclitaxel Plus Gemcitabine (Induction Period) vs Nab-Paclitaxel Plus Gemcitabine (Overall): serious adverse events | 38 of 106 | 39 of 106 | 212 | NCT02301143 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): Number of Participants With Positive Programmed Death Ligand 1 (PD-L1) Expression in Baseline Tumor Tissue | 27 of 159 | 0 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): deaths from any cause | 15 of 159 | 3 of 41 | 200 | NCT03565991 | Trial comparisons |
| Cohort 1 (BRCA 1/2 Defect) vs Cohort 2 (ATM Defect): serious adverse events | 50 of 159 | 7 of 41 | 200 | NCT03565991 | Trial comparisons |
| Trametinib + Gemcitabine vs Placebo + Gemcitabine: serious adverse events | 42 of 80 | 37 of 80 | 160 | NCT01231581 | Trial comparisons |
| Olaparib 300 mg Twice Daily (bd) vs Placebo: deaths from any cause | 68 of 92 | 52 of 62 | 154 | NCT02184195 | Trial comparisons |
| Olaparib 300 mg Twice Daily (bd) vs Placebo: serious adverse events | 28 of 90 | 10 of 61 | 151 | NCT02184195 | Trial comparisons |
| Arm A (Cetuximab, Gemcitabine, Capecitabine, Radiation) vs Arm B (Bevacizumab, Gemcitabine, Capecitabine, Radiation): serious adverse events | 54 of 67 | 51 of 63 | 130 | NCT00305877 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021040/comparisons